Nano formulations for peptide drug delivery: Overcoming bioavailability and stability challenges
Research Scientist III, Analytical R & D, Amneal Pharmaceuticals, NJ, USA.
Research Article
World Journal of Advanced Research and Reviews, 2024, 22(01), 2032-2044
Publication history:
Received on 12 February 2024; revised on 23 April 2024; accepted on 25 April 2024
Abstract:
Peptide-based pharmaceuticals serve as essential therapeutic agents for addressing different conditions such as cancer together with diabetes and infectious diseases. Clinical therapeutic use of peptides is restricted by meager bioavailability, quick enzymatic breakdown, and weak stability. Direct injection and chemical modification methods have revealed a restricted capacity for overcoming these delivery barriers. Nanoformulations establish themselves as promising approaches to address limitations related to peptide drug delivery. Nanocarrier systems composed of liposomes, polymeric nanoparticles, and solid lipid nanoparticles provide better stability functions with delayed release kinetics and enhanced absorption through biological barriers. Drugs formulated into such treatments protect peptides from enzyme breakdown while extending their presence in the bloodstream, resulting in superior therapeutic outcomes. The review investigates modern developments in nano-based peptide transport by analyzing progressive formulation techniques, presenting research conclusions, and predicting clinical usage. The review also addresses obstacles when translating nanocarriers to clinical usage while outlining future development strategies to optimize peptide therapeutic nano-formulations.
Keywords:
Peptide Stability; Nanoformulation Strategies; Targeted Delivery; Polymer Nanoparticles; Lipid Carriers; Controlled Release
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0